https://en.bioecon.ru/companies/lonza/Recent content in Lonza on BioeconHugoen-USSun, 26 Jul 2026 03:42:16 +0700https://en.bioecon.ru/technology/microcarriers-adherent-cell-culture/Sat, 25 Jul 2026 20:30:33 +0000https://en.bioecon.ru/technology/microcarriers-adherent-cell-culture/Small (100–300 μm) suspended particles whose surface lets anchorage-dependent cells grow inside ordinary stirred-tank and single-use bioreactors — the consumable that turns adherent biology (vaccines, cell therapy, cultivated meat) into a scalable, GMP industrial process.https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical sequences — anchored by Codexis’s CodeEvolver platform (the Merck sitagliptin transaminase case) in the US, Almac’s biocatalysis CDMO in the UK, Lonza’s HPAPI/biocatalysis toolkit in Switzerland, and Asymchem and WuXi AppTec’s biocatalysis-enabled CDMO platforms in China.https://en.bioecon.ru/technology/media-manufacturing-equipment/Mon, 06 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/media-manufacturing-equipment/GMP equipment lines for B2B dry-powder and liquid cell-culture media — cryogenic pin milling, ribbon-blend homogenisation and 0.1 um sterile fill — supplying the chemically-defined, animal-component-free media demand of mAb and cell-therapy biomanufacturing.https://en.bioecon.ru/technology/bioproduction-cdmo-cmo/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/bioproduction-cdmo-cmo/Contract development and manufacturing organizations providing specialized infrastructure for advanced biopharmaceuticals.https://en.bioecon.ru/technology/local-manufacturing-for-market-access/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/local-manufacturing-for-market-access/Contract development, technology-transfer and local-build services that establish in-country or regional biomanufacturing so a biologic or vaccine qualifies for market access, procurement preference and supply security in target jurisdictions.